Conmed (CNMD) Misses Q2 EPS by 8c, Maintains FY15 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Northland Capital Markets Downgrades CONMED (CNMD) to Market Perform
July 22, 2015 7:19 AM EDTNorthland Capital Markets downgraded CONMED (NASDAQ: CNMD) from Outperform to Market Perform with a price target of $58.00 (from $65.00), saying 2nd-half guidance may be too optimistic.
Analyst Mark Landy commented, "CNMD reported in line 2Q revenues of $181M but missed our and the... More
Needham & Company Raises Price Target to $60 Following Conmed's (CNMD) 2Q Miss
July 22, 2015 6:58 AM EDTNeedham & Company reiterated a Buy rating on CONMED (NASDAQ: CNMD), and raised the price target to $60.00 (from $56.00), following 2Q15. CNMD's reported revenue was $181.0M vs. consensus of $182.3M. EPS was $0.36 vs. consensus of $0.44. Analyst Mike Matson said that investors may give management the benefit of... More
